The Food and Drug Administration granted priority review designation on Thursday to Eisai's TREM2-targeting Alzheimer's drug candidate, setting a target decision timeline of approximately six months from the submission date and signalling the agency's assessment that the drug may offer a substantial improvement over existing therapies for a disease with severely limited treatment options.
Priority review status is granted to fewer than a quarter of new drug applications. Its award reflects an FDA determination that the drug addresses a serious condition and may represent a meaningful advance. The PDUFA date — the agency's statutory target for a final decision — falls approximately six months from the point of submission, meaning that if the agency meets that target, a decision could be reached before the end of the calendar year.
The drug targets TREM2, a protein that regulates the brain's immune response. In a phase 3 trial enrolling 2,400 participants with early-stage Alzheimer's disease, the drug slowed cognitive decline by 38 percent compared to placebo over 18 months — a primary endpoint result that the FDA's priority review letter described as "clinically meaningful." The agency also noted that the drug appeared to reduce neuroinflammation alongside amyloid accumulation, which it characterised as potentially representing "a meaningful mechanistic advance" over purely amyloid-targeting therapies.
Patient advocacy organisations representing Alzheimer's patients and their families responded to the priority review announcement with what several described as cautious but genuine optimism. "Alzheimer's patients and their families have been waiting a very long time for a treatment that actually works," said the executive director of one major patient advocacy group. "Today's news does not guarantee approval, but it moves the clock significantly faster. That matters to real people."
Brain swelling, technically ARIA, occurred in 8 percent of trial participants — a safety signal that the FDA's priority review letter acknowledged and said would be subject to full evaluation in the review process. Eisai described the rate as within a manageable range and noted that clinical protocols for monitoring and managing ARIA exist across the anti-amyloid drug class.
The priority review designation does not guarantee approval. The full review process involves detailed evaluation of both safety and efficacy data and may result in requests for additional information. Eisai said it had begun discussions with payers and health systems about potential access pathways in preparation for a possible commercial launch.
Shares in Eisai rose 31 percent following the announcement, with analysts citing the priority review designation and the strength of the primary efficacy endpoint as the primary drivers of the move.